MINI LONG - NOVO-NORDISK B | Real-time Bid/Ask 04:18:06 2024-07-01 EDT | ||
| 15.49 EUR / 15.5 EUR | +1.27% |
|
| Current month | +14.86% | ||
| 1 month | +14.95% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 15.3 | -1.03% |
| 24-06-27 | 15.46 | -0.64% |
| 24-06-26 | 15.56 | -2.38% |
| 24-06-25 | 15.94 | +6.84% |
| 24-06-24 | 14.92 | -1.32% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 02:48 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MD9XZ7 |
| ISIN | DE000MD9XZ72 |
| Date issued | 2022-10-27 |
| Strike | 429.3 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.6 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.01 € |
|---|---|
| Lowest since issue | 0.32 € |
| Spread | 0.01 € |
| Spread % | 0.06% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Certificates
- Certificat
